ASAD MEHDI: Open Payments
NPI 1578779898 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,256 in 194 payments from 20 companies in 2025. Trend: 2023 $2,653 · 2024 $2,478 · 2025 $3,256
Food & beverage: $3,250Education: $5
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 29 | $351 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $320 |
| ABBVIE INC. | 21 | $318 |
| Lundbeck LLC | 13 | $311 |
| Otsuka America Pharmaceutical, Inc. | 16 | $301 |
| Janssen Pharmaceuticals, Inc | 12 | $207 |
| Alkermes, Inc. | 9 | $207 |
| Neurocrine BioSciences, Inc. | 11 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $186 |
| E.R. Squibb & Sons, L.L.C. | 9 | $178 |
Products named: CAPLYTA, VRAYLAR, ABILIFY ASIMTUFII, REXULTI, INGREZZA, UZEDY, ARISTADA, TRINTELLIX.
Industry payments across GA — which companies pay providers there.
